Publications by authors named "Mark Bondin"

Claim this Profile
U
Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis.
Markus Cornberg, Dietrich Hüppe, Christoph Sarrazin, Adriana Ahumada, Francisco Jorquera Plaza, Mark Bondin

Adv Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.
Jordan J Feld, Xavier Forns, Douglas E Dylla, Hiromitsu Kumada, Victor de Ledinghen, Mark Bondin

J Viral Hepat· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir.
Alessio Aghemo, Yves Horsmans, Stefan Bourgeois, Mark Bondin, Michael Gschwantler

Infect Dis Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir.
Alessio Aghemo, Yves Horsmans, Stefan Bourgeois, Mark Bondin, Michael Gschwantler

Infect Dis Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).
Dietrich Hüppe, Albrecht Stoehr, Peter Buggisch, Stefan Mauss, Hartwig Klinker, Mark Bondin

J Viral Hepat· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry.
Hartwig Klinker, Uwe Naumann, Martin Rössle, Thomas Berg, Mark Bondin

Liver Int· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks' Glecaprevir/Pibrentasvir Therapy.
Massimo Andreoni, Giovanni Di Perri, Marcello Persico, Andrea Marcellusi, Olivier Ethgen, Mark Bondin

Infect Dis Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.
Xavier Forns, Jordan J Feld, Douglas E Dylla, Stanislas Pol, Kazuaki Chayama, Mark Bondin

Adv Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
Pietro Lampertico, Stefan Mauss, Marcello Persico, Stephen T Barclay, Steven Marx, Mark Bondin

Adv Ther· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
Pietro Lampertico, Stefan Mauss, Marcello Persico, Stephen T Barclay, Steven Marx, Mark Bondin

Adv Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials.
Fred Poordad, RuiSarmento E Castro, Armen Asatryan, Humberto Aguilar, Patrice Cacoub, Mark Bondin

J Viral Hepat· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
Robert J Fontana, Sabela Lens, Stuart McPherson, Magdy Elkhashab, Victor Ankoma-Sey, Mark Bondin

Adv Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert opinion on managing chronic HCV in patients with non-Hodgkin lymphoma and other extrahepatic malignancies.
Clodoveo Ferri, Jordan J Feld, Mark Bondin, Patrice Cacoub

Antivir Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations.
Daniel Forton, Karin Weissenborn, Mark Bondin, Patrice Cacoub

Antivir Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert opinion on managing chronic HCV in patients with mixed cryoglobulinaemia vasculitis.
Anna Linda Zignego, Jean-Michel Pawlotsky, Mark Bondin, Patrice Cacoub

Antivir Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert opinion on managing chronic HCV in patients with cardiovascular disease.
Cristina Vassalle, Salvatore Petta, Alessia Pepe, Antonio Craxi, Mark Bondin

Antivir Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert opinion on the management of renal manifestations of chronic HCV infection.
Fabrizio Fabrizi, Francesco Negro, Mark Bondin, Patrice Cacoub

Antivir Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert opinion on managing chronic HCV infection in patients with type 2 diabetes mellitus.
Luigi Elio Adinolfi, Ira Jacobson, Mark Bondin, Patrice Cacoub

Antivir Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
David Back, Pamela Belperio, Mark Bondin, Francesco Negro, Andrew H Talal

J Viral Hepat· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
Peter Ferenci, Stefan Bourgeois, Peter Buggisch, Suzanne Norris, Manuela Curescu, Mark Bondin

J Viral Hepat· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electrocatalytic proton reduction by phosphido-bridged diiron carbonyl compounds: distant relations to the H-cluster?
Mun Hon Cheah, Stacey J Borg, Mark I Bondin, Stephen P Best

Inorg Chem· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis